Evidence map›Paper›PMID 38662435›Full record

ArticleThe Journal of clinical investigation2024

Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.

Xiaochao Tan, Shike Wang, Guan-Yu Xiao, Chao Wu, Xin Liu, Biyao Zhou, Yu Jiang, Dzifa Y Duose, Yuanxin Xi, Jing Wang and 8 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Golgi Drivers of Cancer.Sub-cellular biochemistry · 2026
    Review
  4. Monensin suppresses EMT-driven cancer cell motility by inducing Golgi pH-dependent exocytosis of GOLIM4.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Article
  7. Review
  8. Targeting the secretory program of 3q-amplified lung cancers.The Journal of clinical investigation · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Xiaochao TanDepartment of Thoracic/Head and Neck Medical Oncology.
Shike WangDepartment of Thoracic/Head and Neck Medical Oncology.
Guan-Yu XiaoDepartment of Thoracic/Head and Neck Medical Oncology.
Chao WuDepartment of Thoracic/Head and Neck Medical Oncology.
Xin LiuDepartment of Thoracic/Head and Neck Medical Oncology.
Biyao ZhouDepartment of Thoracic/Head and Neck Medical Oncology.
Yu JiangDepartment of Thoracic/Head and Neck Medical Oncology.
Dzifa Y DuoseDepartment of Translational Molecular Pathology, and.
Yuanxin XiDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kunika GuptaDepartment of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, India.
Apar PataerDepartment of Thoracic and Cardiovascular Surgery and.
Jack A RothDepartment of Thoracic and Cardiovascular Surgery and.
Michael P KimDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fengju ChenDepartment of Medicine and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
Chad J CreightonDepartment of Medicine and Dan L Duncan Cancer Center, Baylor College of Medicine, Houston, Texas, USA.
William K RussellDepartment of Biochemistry and Molecular Biology, The University of Texas Medical Branch, Galveston, Texas, USA.
Jonathan M KurieDepartment of Thoracic/Head and Neck Medical Oncology.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USTata Institute of Fundamental Research · INThe University of Texas Medical Branch at Galveston · US

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
UCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jack Roth · 2017 to 2026
$12.9M
A pro-metastatic secretory pathway activated by p53 loss in lung cancerR01CA255021 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2021 to 2025
$2.4M
Regulation of lung cancer growth and metastasis by an actionable driver of vesicle biogenesis in the GolgiR01CA236781 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2020 to 2024
$2.2M
A pro-metastatic secretory program activated by epithelial-to-mesenchymal transitionR00CA249048 · NCI · UNIVERSITY OF KENTUCKY · PI GUAN-YU XIAO · 2024 to 2026
$747k
An actionable secretory program that drives tumor progression in a genetically defined subset of lung squamous carcinomaR03CA280382 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TAN, XIAOCHAO · 2023 to 2024
$158k
NCI NIH HHS P30 CA125123NCI NIH HHS R00 CA249048NCI NIH HHS R01 CA236781NCI NIH HHS R01 CA255021NCI NIH HHS R03 CA280382NCI NIH HHS U54 CA224081
6 · The paper itself

Abstract

Cancer cells exhibit heightened secretory states that drive tumor progression. Here, we identified a chromosome 3q amplicon that serves as a platform for secretory regulation in cancer. The 3q amplicon encodes multiple Golgi-resident proteins, including the scaffold Golgi integral membrane protein 4 (GOLIM4) and the ion channel ATPase secretory pathway Ca2+ transporting 1 (ATP2C1). We show that GOLIM4 recruited ATP2C1 and Golgi phosphoprotein 3 (GOLPH3) to coordinate Ca2+-dependent cargo loading, Golgi membrane bending, and vesicle scission. GOLIM4 depletion disrupted the protein complex, resulting in a secretory blockade that inhibited the progression of 3q-amplified malignancies. In addition to its role as a scaffold, GOLIM4 maintained intracellular manganese (Mn) homeostasis by binding excess Mn in the Golgi lumen, which initiated the routing of Mn-bound GOLIM4 to lysosomes for degradation. We show that Mn treatment inhibited the progression of multiple types of 3q-amplified malignancies by degrading GOLIM4, resulting in a secretory blockade that interrupted prosurvival autocrine loops and attenuated prometastatic processes in the tumor microenvironment. As it potentially underlies the selective activity of Mn against 3q-amplified malignancies, ATP2C1 coamplification increased Mn influx into the Golgi lumen, resulting in a more rapid degradation of GOLIM4. These findings show that functional cooperativity between coamplified genes underlies heightened secretion and a targetable secretory addiction in 3q-amplified malignancies.

Indexed as

Chromosomes, Human, Pair 3Membrane ProteinsNeoplasm ProteinsNeoplasmsSecretory VesiclesAnimalsCalcium-Transporting ATPasesCell Line, TumorGolgi ApparatusHumansManganeseMiceATP2C1 protein, humanCalcium-Transporting ATPasesGOLPH3 protein, humanManganeseMembrane ProteinsNeoplasm ProteinsCancer gene therapyCell biologyLung cancerOncologyProtein traffic

Identifiers

PMID38662435
PMCPMC11178546
OpenAlexW4395477939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.